Pharming Group N.V.

ENXTAM:PHARM Stock Report

Market Cap: €471.5m

Pharming Group Management

Management criteria checks 2/4

Pharming Group's CEO is Simon de Vries, appointed in Nov 2008, has a tenure of 16.08 years. total yearly compensation is $2.81M, comprised of 24% salary and 76% bonuses, including company stock and options. directly owns 2.13% of the company’s shares, worth €10.05M. The average tenure of the management team and the board of directors is 3.8 years and 3.7 years respectively.

Key information

Simon de Vries

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage24.0%
CEO tenure16yrs
CEO ownership2.1%
Management average tenure3.8yrs
Board average tenure3.7yrs

Recent management updates

Recent updates

Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Feb 14
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Nov 11
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Aug 23
Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate

Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Jun 20
Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Mar 16
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

Feb 17
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price

We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Dec 08
We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Aug 05
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

Mar 21
Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next

These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Mar 19
These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat

Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Feb 20
Is Pharming Group (AMS:PHARM) Using Too Much Debt?

Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Oct 29
Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price

Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Jun 03
Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly

Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

May 12
Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)

CEO Compensation Analysis

How has Simon de Vries's remuneration changed compared to Pharming Group's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$18m

Jun 30 2024n/an/a

-US$13m

Mar 31 2024n/an/a

-US$11m

Dec 31 2023US$3mUS$673k

-US$11m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$16m

Mar 31 2023n/an/a

-US$2m

Dec 31 2022US$2mUS$636k

US$14m

Sep 30 2022n/an/a

US$30m

Jun 30 2022n/an/a

US$21m

Mar 31 2022n/an/a

US$11m

Dec 31 2021US$3mUS$681k

US$16m

Sep 30 2021n/an/a

US$22m

Jun 30 2021n/an/a

US$31m

Mar 31 2021n/an/a

US$37m

Dec 31 2020US$3mUS$614k

US$38m

Sep 30 2020n/an/a

US$44m

Jun 30 2020n/an/a

US$46m

Mar 31 2020n/an/a

US$42m

Jan 01 2020n/an/a

US$41m

Sep 30 2019n/an/a

US$38m

Jun 30 2019n/an/a

US$34m

Mar 31 2019n/an/a

US$29m

Dec 31 2018US$2mUS$579k

US$29m

Sep 30 2018n/an/a

-US$29m

Jun 30 2018n/an/a

-US$44m

Mar 31 2018n/an/a

-US$80m

Dec 31 2017US$2mUS$537k

-US$91m

Compensation vs Market: Simon's total compensation ($USD2.81M) is above average for companies of similar size in the Dutch market ($USD873.34K).

Compensation vs Earnings: Simon's compensation has increased whilst the company is unprofitable.

CEO

Simon de Vries (65 yo)

16yrs

Tenure

US$2,809,000

Compensation

Dr. Sijmen De Vries, also known as Simon, M. D., M. B.A., has been the Chief Executive Officer of Pharming Group N. V. since November 03, 2008 and also serves as its Executive Director since October 13, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Sijmen de Vries
President16yrsUS$2.81m2.13%
€ 10.1m
Jeroen Wakkerman
Chief Financial Officer4yrsno data0.064%
€ 299.4k
Mireille Sanders
Chief Operations Officer5.3yrsno data0.12%
€ 555.3k
Susanne Embleton
Investor Relations Managerno datano datano data
Ruud Van Outersterp
Chief Ethics & Compliance Officer3.5yrsno data0.024%
€ 114.8k
Anurag Relan
Chief Medical Officer3.4yrsno data0.027%
€ 128.0k
Stephen Toor
Chief Commercial Officer & GM Americas7.8yrsno data0.028%
€ 130.5k
Alexander Breidenbach
Chief Business Officer1.2yrsno data0.0096%
€ 45.4k
Bruno M. Giannetti
Consultant3.4yrsno datano data

3.8yrs

Average Tenure

58yo

Average Age

Experienced Management: PHARM's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sijmen de Vries
President16.1yrsUS$2.81m2.13%
€ 10.1m
Leonard Kruimer
Independent Non-Executive Director3.5yrsUS$90.00k0.018%
€ 84.2k
Mark Pykett
Independent Non-Executive Director3.9yrsUS$87.00k0.022%
€ 101.5k
Deborah Jorn
Independent Non-Executive Vice-Chairperson5.5yrsUS$87.00k0.024%
€ 112.3k
Steven Baert
Independent Non-Executive Director3.5yrsUS$90.00k0.018%
€ 84.2k
Barbara Yanni
Independent Non-Executive Director3.9yrsUS$94.00k0.022%
€ 101.5k
Richard Peters
Non-Executive Chairman of Board1.2yrsUS$46.00k0.0093%
€ 43.7k
Jabine van der Meijs
Independent Non-Executive Director3.5yrsUS$94.00k0.018%
€ 84.2k

3.7yrs

Average Tenure

63yo

Average Age

Experienced Board: PHARM's board of directors are considered experienced (3.7 years average tenure).